New therapeutic options for mesothelioma

Current Oncology Reports

Volumn 7, Issue 4, 2005, Pages 260-265

  Goudar, Ranjit Kumar ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DEXAMETHASONE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLAVOPIRIDOL; FOLIC ACID; FR 901228; GEMCITABINE; METHOTREXATE; MITOMYCIN C; OXALIPLATIN; PACLITAXEL; PEMETREXED; PHOTOFRIN; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; RALTITREXED; RANPIRNASE; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA2; SEMAXANIB; SORAFENIB; TEMOPORFIN; THYMIDINE KINASE; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR; ANTINEOPLASTIC AGENT;

ARTHRALGIA; ASTHENIA; BEAM THERAPY; BIOCHEMISTRY; BONE MARROW SUPPRESSION; BRONCHOPLEURAL FISTULA; CANCER CELL CULTURE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DRUG ERUPTION; DRUG TARGETING; FATIGUE; GASTROINTESTINAL DISEASE; HERPES SIMPLEX VIRUS; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LEUKOPENIA; LUNG RESECTION; MEDIASTINUM DISEASE; MEDICAL DECISION MAKING; META ANALYSIS; METASTASIS POTENTIAL; MORBIDITY; MULTIMODALITY CANCER THERAPY; NAUSEA AND VOMITING; NEUTROPENIA; PAIN; PERIPHERAL EDEMA; PHOTODYNAMIC THERAPY; PLEURA MESOTHELIOMA; QUALITY OF LIFE; RADIATION DOSE; REVIEW; SYSTEMATIC REVIEW; ADJUVANT THERAPY; MESOTHELIOMA; PHOTOCHEMOTHERAPY; PLEURA TUMOR;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; MESOTHELIOMA; NEOADJUVANT THERAPY; PHOTOCHEMOTHERAPY; PLEURAL NEOPLASMS;

EID: 23444444907     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-005-0048-3     Document Type: Review

References (46)

1. Group USCSW. United States Cancer Statistics: 2001 Incidence and Mortality. Atlanta, GA. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2004.
2. Price B, Ware A: Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003. Am J Epidemiol 2004, 159:107-112.
3. Pass HI, Vogetzang N, Hahn S, Carbone M: Malignant pleural mesothelioma. Curr Probl Cancer 2004, 28:93-174.
4. Rusch VW, Venkatraman ES: Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg 1999, 68:1799-1804.
5. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al.: Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999, 117:54-63.
6. Sugarbaker DJ, Jaklitsch MT, Bueno R, et al.: Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg 2004, 128:138-146.
7. Kukreja J, Jaklitsch MT, Wiener DC, et al.: Malignant pleural mesothelioma: overview of the North American and European experience. Thorac Surg Clin 2004, 14:435-445.
8. Monneuse O, Beaujard AC, Guibert B, et al.: Long-term results of intrathoracic chemohyperthermia (ITCH) for the treatment of pleural malignancies. Br J Cancer. Jun 16 2003, 88(12):1839-1843.
9. Chang MY, Sugarbaker DJ: Innovative therapies: intraoperative intracavitary chemotherapy. Thorac Surg Clin 2004, 14:549-556.
10. Sugarbaker D, Richards WD, Zellos LS, et al.: Feasibility of pleurectomy and intraoperative bicavitary hyperthermic cisplatin lavage for mesothelioma [abstract]. Proc ASCO 2003, 22:2494.
11. Fingar VH, Taber SW, Haydon PS, et al.: Vascular damage after photodynamic therapy of solid tumors: a view and comparison of effect in pre-clinical and clinical models at the University of Louisville. In Vivo 2000, 14:93-100.
12. Pass HI, Temeck BK, Kranda K, et al.: Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. Ann Surg Oncol 1997, 4:628-633.
13. Rodriguez E, Baas P, Friedberg JS: Innovative therapies: photodynamic therapy. Thorac Surg Clin 2004, 14:557-566.
14. Friedberg JS, Mick R, Stevenson J, et al.: A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma. Ann Thorac Surg Mar 2003, 75(3):952-959.
15. Yom SS, Busch TM, Friedberg JS, et al.: Elevated serum cytokine levels in mesothelioma patients who have undergone pleurectomy or extrapleural pneumonectomy and adjuvant intraoperative photodynamic therapy. Photochem Photobiol 2003, 78:75-81.
16. Weder W, Kestenholz P, Taverna C, et al.: Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 2004, 22:3451-3457.
17. Utkan G, Yalcin B, Buyukcelik A, Yalcin S: Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma: is it safe? J Clin Oncol 2005, 23:655.
18. Baldini EH: External beam radiation therapy for the treatment of pleural mesothelioma. Thorac Surg Clin 2004, 14:543-548.
19. Ball DL, Cruickshank DG: The treatment of malignant mesothelioma of the pleura: review of a 5-year experience, with special reference to radiotherapy. Am J Clin Oncol 1990, 13:4-9.
20. de Graaf-Strukowska L, van der Zee J, van Putten W, Senan S: Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura: a single-institution experience with 189 patients. Int J Radiat Oncol Biol Phys 1999, 43:511-516.
21. Tobler M, Watson G, Leavitt DD: Intensity-modulated photon arc therapy for treatment of pleural mesothelioma. Med Dosim 2002, 27:255-259.
22. Lee TT, Everett DL, Shu HK, et al.: Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2002, 124:1183-1189.
23. Rusch VW, Rosenzweig K, Venkatraman E, et al.: A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001, 122:788-795.
24. Forster KM, Smythe WR, Starkschall G, et al.: Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation. Int J Radiat Oncol Biol Phys 2003, 55:606-616.
25. Boutin C, Rey F, Viallat JR: Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma: a randomized trial of local radiotherapy. Chest 1995, 108:754-758.
26. Lo TC, Cassady J, Beamis JF: Single dose electron beam radiation therapy for tumor wound seeding prophylaxis in mesothelioma [abstract]. Proc ASCO 2004, 23:7238.
27. Berghmans T, Paesmans M, Lalami Y, et al.: Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 2002, 38:111-121.
28. Favaretto AG, Aversa SM, Paccagnella A, et al.: Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study. Cancer 2003, 97:2791-2797.
29. Baas P, Ardizzoni A, Grossi F, et al.: The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992). Eur J Cancer 2003, 39:353-357.
30. van Meerbeeck JP, Manegold C, Gaafar R, et al.: A randomized phase III of cisplatin with or without raltitrexed in patients (pts) with malignant pleural mesothelioma (MPM): an intergroup study of the EORTC Lung Cancer Group and NCIC [abstract]. Proc ASCO 2004, 23:7021.
31. Vogelzang NJ: Multimodality therapy in mesothelioma: role of chemotherapy. Thorac Surg Clin 2004, 14:531-542.
32. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al.: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21:2636-2644.
33. Hazarika M, White RM, Johnson JR, Pazdur R: FDA drug approval summaries: pemetrexed (Alimta). Oncologist 2004, 9:482-488.
34. Paoletti P, Pistolesi M, Rusthoven J, et al.: Correlation of pulmonary function tests with best tumor response status: results from the phase III study of pemetrexed + cisplatin vs. cisplatin in malignant pleural mesothelioma [abstract]. Proc ASCO 2003, 22:659.
35. Steele JP: The new front line treatment for malignant pleural mesothelioma? Thorax 2003, 58:96-97.
36. Harrison LH Jr, Schwarzenberger PO, Byrne PS, et al.: Gene-modified PA1-STK cells home to tumor sites in patients with malignant pleural mesothelioma. Ann Thorac Surg 2000, 70:407-411.
37. Strizzi L, Catalano A, Vianale G, et al.: Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001, 193:468-475.
38. Ohta Y, Shridhar V, Bright RK, et al.: VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 1999, 81d:54-61.
39. Kindler HL, Vogelzang NJ, Chien K et al.: SU5416 in malignant mesothelioma: a University of Chicago phase II consortium study [abstract]. Proc ASCO 2001, 20:1359.
40. Kindler HL: Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma. Lung Cancer 2004, 45 (Suppl 1):S125-127.
41. Govindan R RJ, Suppiah R: EGFR and HER-2 overexpression in malignant mesothelioma [abstract]. Proc ASCO 2001, 20:3106.
42. Versnel MA, Claesson-Welsh L, Hammacher A, et al.: Human malignant mesothelioma cell lines express PDGF beta-receptors whereas cultured normal mesothelial cells express predominantly PDGF alpha-receptors. Oncogene 1991, 6:2005-2011.
43. Suzuki E, Kapoor V, Cheung HK et al.: Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity. Clin Cancer Res 2004, 10:5907-5918.
44. Mikulski SM, Costanzi JJ, Vogelzang NJ, et al.: Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol 2002, 20:274-281.
45. Yu X, Guo ZS, Marcu MG, et al.: Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 2002, 94:504-513.
46. Nguyen DM, Schrump WD, Chen GA, et al.: Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. Clin Cancer Res 2004, 10:1813-1825.